A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
AIM: To assess the safety and efficacy of the combined treatment of reduced-fluence verteporfin photodynamic therapy (PDT), intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for choroidal neovascularisa- tion (CNV) secondary to age-related macular degeneration (AMD). METHODS...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797052941316653056 |
|---|---|
| author | Sivaprasad, S Patra, S DaCosta, J Adewoyin, T Shona, O Pearce, E Chong, N |
| author_facet | Sivaprasad, S Patra, S DaCosta, J Adewoyin, T Shona, O Pearce, E Chong, N |
| author_sort | Sivaprasad, S |
| collection | OXFORD |
| description | AIM: To assess the safety and efficacy of the combined treatment of reduced-fluence verteporfin photodynamic therapy (PDT), intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for choroidal neovascularisa- tion (CNV) secondary to age-related macular degeneration (AMD). METHODS: Nineteen patients with subfoveal CNV secondary to AMD were recruited into the trial. All study eyes (n = 19) received a single cycle of reduced-fluence (25 mJ/cm(2)) PDT with verteporfin followed by an intravitreal injection of ranibizumab 0.3 mg/0.05 ml and dexamethasone 200 μg at baseline. Oral minocycline 100 mg daily was started the following day and continued for 3 months. Patients were followed up monthly for 12 months. Repeat intravitreal ranibizumab was given if best-corrected visual acuity (BCVA) deteriorated by >5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or central retinal thickness (CRT) on ocular coherence tomography increased >100 μm. RESULTS: Eighteen patients completed the 12-month study. Stable vision (loss of ≤15 ETDRS letters) was maintained in 89% eyes (16/18). The mean change in BCVA was -5.0 ± 10.5 ETDRS letters. The mean number of ranibizumab injections was 3.4 (range 2-6). The mean reduction in the CRT was 66.3 μm (±75). CONCLUSION: This open-label clinical trial has demonstrated the safety in terms of adverse effects and maintenance of stable vision of combination treatment with verteporfin, ranibizumab, dexamethasone and minocycline in exudative AMD. However, the outcomes with reduced-fluence PDT combination therapy does not differ significantly with outcomes of clinical trials on combination treatment with standard dose PDT and intravitreal ranibizumab in neovascular AMD. |
| first_indexed | 2024-03-06T18:37:36Z |
| format | Journal article |
| id | oxford-uuid:0bca144a-87bf-42a7-ac6b-3d08336e3b0c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:37:36Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:0bca144a-87bf-42a7-ac6b-3d08336e3b0c2022-03-26T09:31:20ZA pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0bca144a-87bf-42a7-ac6b-3d08336e3b0cEnglishSymplectic Elements at Oxford2011Sivaprasad, SPatra, SDaCosta, JAdewoyin, TShona, OPearce, EChong, N AIM: To assess the safety and efficacy of the combined treatment of reduced-fluence verteporfin photodynamic therapy (PDT), intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for choroidal neovascularisa- tion (CNV) secondary to age-related macular degeneration (AMD). METHODS: Nineteen patients with subfoveal CNV secondary to AMD were recruited into the trial. All study eyes (n = 19) received a single cycle of reduced-fluence (25 mJ/cm(2)) PDT with verteporfin followed by an intravitreal injection of ranibizumab 0.3 mg/0.05 ml and dexamethasone 200 μg at baseline. Oral minocycline 100 mg daily was started the following day and continued for 3 months. Patients were followed up monthly for 12 months. Repeat intravitreal ranibizumab was given if best-corrected visual acuity (BCVA) deteriorated by >5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or central retinal thickness (CRT) on ocular coherence tomography increased >100 μm. RESULTS: Eighteen patients completed the 12-month study. Stable vision (loss of ≤15 ETDRS letters) was maintained in 89% eyes (16/18). The mean change in BCVA was -5.0 ± 10.5 ETDRS letters. The mean number of ranibizumab injections was 3.4 (range 2-6). The mean reduction in the CRT was 66.3 μm (±75). CONCLUSION: This open-label clinical trial has demonstrated the safety in terms of adverse effects and maintenance of stable vision of combination treatment with verteporfin, ranibizumab, dexamethasone and minocycline in exudative AMD. However, the outcomes with reduced-fluence PDT combination therapy does not differ significantly with outcomes of clinical trials on combination treatment with standard dose PDT and intravitreal ranibizumab in neovascular AMD. |
| spellingShingle | Sivaprasad, S Patra, S DaCosta, J Adewoyin, T Shona, O Pearce, E Chong, N A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. |
| title | A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. |
| title_full | A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. |
| title_fullStr | A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. |
| title_full_unstemmed | A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. |
| title_short | A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. |
| title_sort | pilot study on the combination treatment of reduced fluence photodynamic therapy intravitreal ranibizumab intravitreal dexamethasone and oral minocycline for neovascular age related macular degeneration |
| work_keys_str_mv | AT sivaprasads apilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT patras apilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT dacostaj apilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT adewoyint apilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT shonao apilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT pearcee apilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT chongn apilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT sivaprasads pilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT patras pilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT dacostaj pilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT adewoyint pilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT shonao pilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT pearcee pilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration AT chongn pilotstudyonthecombinationtreatmentofreducedfluencephotodynamictherapyintravitrealranibizumabintravitrealdexamethasoneandoralminocyclineforneovascularagerelatedmaculardegeneration |